Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • Log out
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Letters: Observations

LDL Electronegativity Is Enhanced in Type 1 Diabetes

  1. Roberto Gambino, PHD,
  2. Sara Giunti, MD,
  3. Barbara Uberti, PHD,
  4. Paolo Cavallo Perin, MD,
  5. Gianfranco Pagano, MD and
  6. Maurizio Cassader, PHD
  1. From the Dipartimento di Medicina Interna, Università di Torino, Torino, Italy
  1. Address correspondence to Dr. Maurizio Cassader, Dipartimento di Medicina Interna, Università di Torino, Corso AM Dogliotti 14, Torino 10126, Italy.
Diabetes Care 2003 Jul; 26(7): 2214-2215. https://doi.org/10.2337/diacare.26.7.2214
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

LDL particles exhibit heterogeneity in density, size, chemical composition, and charge (1). Lipoperoxidation, oxidation, and glycosylation increase the net negative charge and may enhance LDL atherogenicity with important metabolic consequences. A relevant role of more electronegative LDL in atherogenesis is supported by the observation that it is elevated in subjects at high risk, such as familial hypercholesterolemic and type 1 diabetic patients (2).

We reported the precise measurement of the electrophoretic mobility of LDL as an indicator of modification by capillary electrophoresis and the UV absorption at 234 nm that results from the formation of conjugated dienes in constituent polyenoic fatty acids in 14 type 1 diabetic patients (7 normoalbuminuric and 7 microalbuminuric patients) and in 6 nondiabetic subjects. In type 1 diabetic patients with normoalbuminuria (six men and one woman; mean age 38 ± 12 years) the mean duration of diabetes was 25 ± 7 years, and they were in stable glycemic control (HbA1c = 7.1 ± 0.6%). The seven diabetic patients with microalbuminuria (six men and one woman; mean age 52 ± 9 years, P < 0.01 vs. normoalbuminuric patients) had a mean duration of diabetes of 22 ± 14 years and a mean HbA1c value of 8.8 ± 1% (P < 0.01 vs. normoalbuminuric patients). Diabetic patients had significantly higher BMI (25 ± 2 kg/m2) (P < 0.01 for normoalbuminuric subjects, 25 ± 3 kg/m2; P < 0.05 for microalbuminuric vs. control group, 21 ± 2 kg/m2) and fasting glucose levels (215 ± 83 mg/dl) (P < 0.01 for normoalbuminuric subjects, 197 ± 91 mg/dl; P < 0.01 for microalbuminuric vs. control group, 99 ± 18 mg/dl) than control subjects. There was no difference in triglycerides, total cholesterol, LDL cholesterol, and HDL cholesterol levels between diabetic subjects and the control group.

LDL was isolated by preparative sequential ultracentrifugation at the density of 1.063 g/ml. Dialyses, capillary electrophoresis (CE), and the electrophoretic mobility (μ) of LDL were performed as described by Stock and Miller (3). Migration of LDL particles was monitored at 200 and 234 nm. The amount of conjugated dienes is obtained from the percentage of the height of LDL peak at 234 nm related to the height of LDL peak at 200 nm. Student’s t test and Pearson’s correlation were used to assess statistical significance.

The electrophoretic mobility (mean ± SD) for the diabetic LDL was −1.249 ± 0.065 · 10−4 · cm2 · vol−1 · s−1, while that for the control LDL was −1.032 ± 0.121 (P = 0.0001). The diabetic group, subdivided into normoalbuminuric and microalbuminuric subjects, presented an electrophoretic mobility mean of −1.234 ± 0.068 and −1.263 ± 0.064 · 10−4 · cm2 · vol−1 · s−1, respectively. When each group was compared with the control, the differences were always statistically significant in both cases (P = 0.0032 for normoalbuminuric patients vs. control subjects; P = 0.0001 for microalbuminuric patients vs. control subjects). Diabetic subjects have LDL with significantly higher migration rates, which were independent from microalbuminuria.

In LDL obtained from the diabetic patients the content of diene conjugates was not statistically different from the control group (6.22 ± 1.199% for diabetic subjects vs. 5.509 ± 0.219% for control subjects).

The difference between diabetic and control subjects was still not statistically significant when the content of diene conjugates in normoalbuminuric (6.235 ± 1.544%) and microalbuminuric (6.214 ± 0.854%) subjects was individually compared with that of the control group. In the diabetic group, the electrophoretic mobility was not significantly correlated with HbA1c, duration of diabetes, the subjects’ age, or fasting glucose levels.

The finding of electronegative LDL in type 1 diabetic subjects could be related to the increase of the so-called LDL(−), which is also detectable in normal subjects, although in small amounts (4). Capillary electrophoresis cannot separate the fraction LDL(−) from the bulk of plasma LDL. It gives an estimate of the algebraic sum of the electronegative charges distributed on the surface of LDL particles.

Nonenzymatic glycosylation should, surprisingly, be excluded as a cause of higher LDL electronegativity. In this regard, we found no significant correlation between electrophoretic mobility and HbA1c and the fasting plasma glucose levels in the diabetic group. Furthermore, neither the duration of diabetes nor subject age had effects on LDL mobility. Thus, the increased negative charge could be related to compositional abnormalities or other modifications not evaluated in this report, such as an enrichment in sialic acid. Desialylated LDL is more resistant to copper oxidation than native LDL (5).

In conclusion, the finding of more electronegative LDL in diabetic subjects could be an additional risk factor for atherosclerosis in diabetes. Investigations are under way to assess if electrophoretic mobility of LDL in type 1 diabetes can be decreased by further lowering HbA1c levels.

Footnotes

  • DIABETES CARE

References

  1. ↵
    La Belle M, Blanche PJ, Krauss M: Charge properties of low density lipoprotein subclasses. J Lipid Res 38:690–700, 1997
    OpenUrlAbstract
  2. ↵
    Sánchez-Quesada JL, Pérez A, Caixàs A, Ordóñez-Llanos J, Carreras G, Payés A: Electronegative low density lipoprotein subform is increased in patients with short-duration IDDM and is closely related to glycaemic control. Diabetologia 39:1469–1476, 1996
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Stock J, Miller NE: Capillary electrophoresis to monitor the oxidative modification of LDL. J Lipid Res 39:1305–1309, 1998
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Demuth K, Myara I, Chappey B, Vedie B. Pech-Amsellem MA, Haberland ME, Moatti N: A cytotoxic electronegative LDL subfraction is present in human plasma. Arterioscl Thromb Vasc Biol 16:773–783, 1996
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Myara I, Haberland ME, Demuth K, Chappey B, Moatti N: Susceptibility to copper oxidation of neuraminidase-treated LDL. Clin Chem Acta 240:221–223, 1995
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Diabetes Care: 26 (7)

In this Issue

July 2003, 26(7)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
LDL Electronegativity Is Enhanced in Type 1 Diabetes
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
LDL Electronegativity Is Enhanced in Type 1 Diabetes
Roberto Gambino, Sara Giunti, Barbara Uberti, Paolo Cavallo Perin, Gianfranco Pagano, Maurizio Cassader
Diabetes Care Jul 2003, 26 (7) 2214-2215; DOI: 10.2337/diacare.26.7.2214

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

LDL Electronegativity Is Enhanced in Type 1 Diabetes
Roberto Gambino, Sara Giunti, Barbara Uberti, Paolo Cavallo Perin, Gianfranco Pagano, Maurizio Cassader
Diabetes Care Jul 2003, 26 (7) 2214-2215; DOI: 10.2337/diacare.26.7.2214
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Weight Gain and Gestational Diabetes Mellitus Is a Sensitive Issue
  • Beneficial Effects of a 4-Week Exercise Program on Plasma Concentrations of Adhesion Molecules
  • Malignant Melanoma Misdiagnosed as a Diabetic Foot Ulcer
Show more Letters: Observations

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.